UBS Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.07M | Sell |
769,471
-102,063
| -12% | -$140K | ﹤0.01% | 5504 |
|
|
2025
Q4 | $1.4M | Sell |
871,534
-2,774,699
| -76% | -$5.81M | ﹤0.01% | 5280 |
|
|
2025
Q3 | $9.95M | Buy |
3,646,233
+3,006,771
| +470% | +$10M | ﹤0.01% | 3294 |
|
|
2025
Q2 | $2.33M | Buy |
639,462
+47,052
| +8% | +$129K | ﹤0.01% | 4653 |
|
|
2025
Q1 | $1.14M | Buy |
592,410
+241,319
| +69% | +$493K | ﹤0.01% | 5173 |
|
|
2024
Q4 | $667K | Buy |
351,091
+197,429
| +128% | +$343K | ﹤0.01% | 5641 |
|
|
2024
Q3 | $203K | Buy |
153,662
+10,834
| +8% | +$14.5K | ﹤0.01% | 5864 |
|
|
2024
Q2 | $146K | Buy |
142,828
+43,490
| +44% | +$53.7K | ﹤0.01% | 5890 |
|
|
2024
Q1 | $182K | Sell |
99,338
-57,692
| -37% | -$92.2K | ﹤0.01% | 5919 |
|
|
2023
Q4 | $195K | Buy |
157,030
+88,302
| +128% | +$90.1K | ﹤0.01% | 5795 |
|
|
2023
Q3 | $78.3K | Sell |
68,728
-2,760
| -4% | -$3.54K | ﹤0.01% | 5994 |
|
|
2023
Q2 | $65.4K | Sell |
71,488
-16,487
| -19% | -$15.9K | ﹤0.01% | 6314 |
|
|
2023
Q1 | $49.3K | Buy |
87,975
+29,220
| +50% | +$22.3K | ﹤0.01% | 6466 |
|
|
2022
Q4 | $34.1K | Sell |
58,755
-73,206
| -55% | -$22.9K | ﹤0.01% | 7115 |
|
|
2022
Q3 | $41K | Buy |
131,961
+1,309
| +1% | +$514 | ﹤0.01% | 6535 |
|
|
2022
Q2 | $46K | Sell |
130,652
-638,786
| -83% | -$268K | ﹤0.01% | 5977 |
|
|
2022
Q1 | $553K | Buy |
769,438
+286,788
| +59% | +$614K | ﹤0.01% | 4611 |
|
|
2021
Q4 | $1.09M | Sell |
482,650
-46,195
| -9% | -$126K | ﹤0.01% | 4313 |
|
|
2021
Q3 | $1.52M | Buy |
528,845
+390,489
| +282% | +$1.11M | ﹤0.01% | 3820 |
|
|
2021
Q2 | $524K | Sell |
138,356
-189,925
| -58% | -$639K | ﹤0.01% | 4696 |
|
|
2021
Q1 | $1.11M | Buy |
328,281
+192,034
| +141% | +$692K | ﹤0.01% | 4142 |
|
|
2020
Q4 | $381K | Sell |
136,247
-33,816
| -20% | -$98.7K | ﹤0.01% | 4815 |
|
|
2020
Q3 | $427K | Buy |
170,063
+39,738
| +30% | +$349K | ﹤0.01% | 4313 |
|
|
2020
Q2 | $1.77M | Sell |
130,325
-27,162
| -17% | -$281K | ﹤0.01% | 2988 |
|
|
2020
Q1 | $1.19M | Sell |
157,487
-65,089
| -29% | -$506K | ﹤0.01% | 3204 |
|
|
2019
Q4 | $1.41M | Sell |
222,576
-94,013
| -30% | -$447K | ﹤0.01% | 3894 |
|
|
2019
Q3 | $1.24M | Buy |
316,589
+61,680
| +24% | +$264K | ﹤0.01% | 3769 |
|
|
2019
Q2 | $1.23M | Buy |
254,909
+107,075
| +72% | +$609K | ﹤0.01% | 3572 |
|
|
2019
Q1 | $1.21M | Sell |
147,834
-36,319
| -20% | -$249K | ﹤0.01% | 3415 |
|
|
2018
Q4 | $1.02M | Buy |
184,153
+24,356
| +15% | +$191K | ﹤0.01% | 3668 |
|
|
2018
Q3 | $1.41M | Buy |
159,797
+27,677
| +21% | +$248K | ﹤0.01% | 3521 |
|
|
2018
Q2 | $1.32M | Sell |
132,120
-60,229
| -31% | -$603K | ﹤0.01% | 3539 |
|
|
2018
Q1 | $1.83M | Buy |
192,349
+76,480
| +66% | +$1.07M | ﹤0.01% | 3215 |
|
|
2017
Q4 | $1.72M | Buy |
115,869
+39,491
| +52% | +$655K | ﹤0.01% | 3323 |
|
|
2017
Q3 | $1.5M | Sell |
76,378
-34,894
| -31% | -$536K | ﹤0.01% | 3363 |
|
|
2017
Q2 | $1.6M | Sell |
111,272
-40,374
| -27% | -$512K | ﹤0.01% | 3199 |
|
|
2017
Q1 | $1.4M | Buy |
151,646
+66,948
| +79% | +$654K | ﹤0.01% | 3255 |
|
|
2016
Q4 | $882K | Sell |
84,698
-14,489
| -15% | -$125K | ﹤0.01% | 3653 |
|
|
2016
Q3 | $898K | Sell |
99,187
-4,280
| -4% | -$36.4K | ﹤0.01% | 3501 |
|
|
2016
Q2 | $774K | Buy |
103,467
+28,059
| +37% | +$245K | ﹤0.01% | 3586 |
|
|
2016
Q1 | $679K | Sell |
75,408
-15,623
| -17% | -$127K | ﹤0.01% | 3549 |
|
|
2015
Q4 | $1.18M | Buy |
91,031
+57,982
| +175% | +$592K | ﹤0.01% | 3278 |
|
|
2015
Q3 | $319K | Sell |
33,049
-33,244
| -50% | -$305K | ﹤0.01% | 4254 |
|
|
2015
Q2 | $682K | Buy |
66,293
+54,417
| +458% | +$464K | ﹤0.01% | 3864 |
|
|
2015
Q1 | $132K | Buy |
11,876
+395
| +3% | +$4.21K | ﹤0.01% | 5203 |
|
|
2014
Q4 | $134K | Buy |
+11,481
| New | +$165K | ﹤0.01% | 5411 |
|
Other funds holding AKBA
VCM
VPM
UBS Group's AKBA Position: Q1 2026 in Review
UBS Group reduced its Akebia Therapeutics (AKBA) stake by 12% in Q1 2026, selling an estimated $140K and leaving 769,471 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5504.
UBS Group first reported a position in AKBA in Q4 2014 and has held it in 46 quarters since. The position peaked at $9.95M in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- UBS Group held 769,471 shares of Akebia Therapeutics worth $1.07M as of Q1 2026.
- UBS Group sold 102,063 Akebia Therapeutics shares in Q1 2026, an estimated $140K.
- Akebia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5504 holding.
- UBS Group first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Akebia Therapeutics position peaked at $9.95M in Q3 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.